Esperion Therapeutics (ESPR) Accounts Payables (2012 - 2026)

Esperion Therapeutics' Accounts Payables history runs 15 years deep, the most recent figure standing at $68.4 million for Q1 2026.

• Quarterly Accounts Payables fell 4.98% year-over-year to $68.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.4 million (down 4.98% YoY) and the FY2025 annual result came in at $65.1 million, up 25.98% from the prior year.
• Accounts Payables was $68.4 million for Q1 2026 at Esperion Therapeutics, up from $65.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $77.5 million in Q3 2025 and bottomed at $12.8 million in Q2 2022.
• A 5-year average of $41.2 million and a median of $31.7 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 56.28% — and 2025, when it jumped 153.21%.
• Esperion Therapeutics' Accounts Payables stood at $23.0 million in 2022, then surged by 37.66% to $31.7 million in 2023, then surged by 62.84% to $51.6 million in 2024, then increased by 25.98% to $65.1 million in 2025, then increased by 5.13% to $68.4 million in 2026.
• Business Quant data shows ESPR's Accounts Payables at $68.4 million in Q1 2026, $65.1 million in Q4 2025, and $77.5 million in Q3 2025.